KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Common Equity (2016 - 2025)

Biomarin Pharmaceutical's Common Equity history spans 17 years, with the latest figure at $6.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 7.58% year-over-year to $6.1 billion, compared with a TTM value of $6.1 billion through Dec 2025, up 7.58%, and an annual FY2025 reading of $6.1 billion, up 7.58% over the prior year.
  • Common Equity for Q4 2025 was $6.1 billion at Biomarin Pharmaceutical, up from $6.1 billion in the prior quarter.
  • The five-year high for Common Equity was $6.1 billion in Q4 2025, with the low at $4.2 billion in Q1 2021.
  • Average Common Equity over 5 years is $5.0 billion, with a median of $4.8 billion recorded in 2023.
  • Biggest YoY gain for Common Equity was 30.89% in 2021; the steepest drop was 4.02% in 2021.
  • Tracing BMRN's Common Equity over 5 years: stood at $4.3 billion in 2021, then grew by 7.91% to $4.6 billion in 2022, then grew by 7.57% to $5.0 billion in 2023, then increased by 14.27% to $5.7 billion in 2024, then grew by 7.58% to $6.1 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Common Equity are $6.1 billion (Q4 2025), $6.1 billion (Q3 2025), and $6.0 billion (Q2 2025).